The price of Cybin Inc (AMEX:CYBN) shares last traded on Wall Street rose 14.62% to $0.63.
Based on available information, 6 analysts follow Cybin Inc (AMEX:CYBN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $0.74, we find $3.50. Given the previous closing price of $0.55, this indicates a potential upside of 536.36 percent. CYBN stock price is now 76.12% away from the 50-day moving average and 72.09% away from the 200-day moving average. The market capitalization of the company currently stands at $151.29M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 0 rate the stock a hold while 6 rate it a buy. Brokers who have rated the stock have averaged $4.17 as their price target over the next twelve months.
A total of 15.71% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYBN stock. A new stake in Cybin Inc shares was purchased by FNY INVESTMENT ADVISERS, LLC during the first quarter worth $88,000. INTEROCEAN CAPITAL GROUP, LLC invested $63,000 in shares of CYBN during the first quarter. In the first quarter, LPL FINANCIAL LLC acquired a new stake in Cybin Inc valued at approximately $18,000. MARIETTA WEALTH MANAGEMENT, LLC acquired a new stake in CYBN for approximately $13,000. HRT FINANCIAL LP purchased a new stake in CYBN valued at around $9,000 in the second quarter. In total, there are 72 active investors with 10.75% ownership of the company’s stock.
A candlestick chart of Cybin Inc (AMEX: CYBN) showed a price of $0.5600 on Monday morning. During the past 12 months, Cybin Inc has had a low of $0.21 and a high of $0.65. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.61, and a quick ratio of 2.61. The fifty day moving average price for CYBN is $0.3620 and a two-hundred day moving average price translates $0.3678 for the stock.
The latest earnings results from Cybin Inc (AMEX: CYBN) was released for Jun, 2023.
Cybin Inc(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
